108 related articles for article (PubMed ID: 29520231)
1. Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells.
Zhu X; Shen X; Qu J; Straubinger RM; Jusko WJ
Front Pharmacol; 2018; 9():84. PubMed ID: 29520231
[TBL] [Abstract][Full Text] [Related]
2. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways.
Miao X; Koch G; Shen S; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
J Pharm Sci; 2024 Jan; 113(1):235-245. PubMed ID: 37918792
[TBL] [Abstract][Full Text] [Related]
3. Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated
Wang X; Niu J; Li J; Shen X; Shen S; Straubinger RM; Qu J
Mol Cell Proteomics; 2018 Apr; 17(4):655-671. PubMed ID: 29358341
[TBL] [Abstract][Full Text] [Related]
4. Proteome characterization of human pancreatic cyst fluid from intraductal papillary mucinous neoplasm by liquid chromatography/tandem mass spectrometry.
Park J; Han D; Do M; Woo J; Wang JI; Han Y; Kwon W; Kim SW; Jang JY; Kim Y
Rapid Commun Mass Spectrom; 2017 Oct; 31(20):1761-1772. PubMed ID: 28815810
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells.
Miao X; Koch G; Ait-Oudhia S; Straubinger RM; Jusko WJ
Front Pharmacol; 2016; 7():421. PubMed ID: 27895579
[TBL] [Abstract][Full Text] [Related]
6. Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry.
Yoshida K; Kuramitsu Y; Murakami K; Ryozawa S; Taba K; Kaino S; Zhang X; Sakaida I; Nakamura K
Anticancer Res; 2011 Jun; 31(6):2103-8. PubMed ID: 21737628
[TBL] [Abstract][Full Text] [Related]
7. Global Proteomic Profiling of Drosophila Ovary: A High-resolution, Unbiased, Accurate and Multifaceted Analysis.
Velentzas AD; Anagnostopoulos AK; Velentzas PD; Mpakou VE; Sagioglou NE; Tsioka MM; Katarachia S; Manta AK; Konstantakou EG; Papassideri IS; Tsangaris GT; Stravopodis DJ
Cancer Genomics Proteomics; 2015; 12(6):369-84. PubMed ID: 26543083
[TBL] [Abstract][Full Text] [Related]
8. A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines.
Mori-Iwamoto S; Kuramitsu Y; Ryozawa S; Taba K; Fujimoto M; Okita K; Nakamura K; Sakaida I
Mol Med Rep; 2008; 1(3):429-34. PubMed ID: 21479428
[TBL] [Abstract][Full Text] [Related]
9. Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma.
Shao F; Huang M; Meng F; Huang Q
Front Pharmacol; 2018; 9():584. PubMed ID: 29922161
[TBL] [Abstract][Full Text] [Related]
10. Anacardic acid inhibits pancreatic cancer cell growth, and potentiates chemotherapeutic effect by Chmp1A - ATM - p53 signaling pathway.
Park M; Upton D; Blackmon M; Dixon V; Craver S; Neal D; Perkins D
BMC Complement Altern Med; 2018 Feb; 18(1):71. PubMed ID: 29463243
[TBL] [Abstract][Full Text] [Related]
11. Isocorydine decrease gemcitabine-resistance by inhibiting epithelial-mesenchymal transition via STAT3 in pancreatic cancer cells.
Zhang QB; Ye RF; Ye LY; Zhang QY; Dai NG
Am J Transl Res; 2020; 12(7):3702-3714. PubMed ID: 32774728
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine.
Yu Y; Ding F; Gao M; Jia YF; Ren L
Oncol Lett; 2019 Sep; 18(3):3065-3071. PubMed ID: 31452783
[TBL] [Abstract][Full Text] [Related]
13. ITRAQ-Based Proteomics Analysis of Triptolide On Human A549 Lung Adenocarcinoma Cells.
Li F; Zhao D; Yang S; Wang J; Liu Q; Jin X; Wang W
Cell Physiol Biochem; 2018; 45(3):917-934. PubMed ID: 29428961
[TBL] [Abstract][Full Text] [Related]
14. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling.
Wang B; Shen C; Li Y; Zhang T; Huang H; Ren J; Hu Z; Xu J; Xu B
Onco Targets Ther; 2019; 12():5751-5765. PubMed ID: 31410021
[No Abstract] [Full Text] [Related]
15. Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.
Gu WJ; Liu HL
Anticancer Drugs; 2013 Jul; 24(6):566-76. PubMed ID: 23525071
[TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways.
Brandi J; Dando I; Pozza ED; Biondani G; Jenkins R; Elliott V; Park K; Fanelli G; Zolla L; Costello E; Scarpa A; Cecconi D; Palmieri M
J Proteomics; 2017 Jan; 150():310-322. PubMed ID: 27746256
[TBL] [Abstract][Full Text] [Related]
17. Use of herbal medicines and natural products: an alternative approach to overcoming the apoptotic resistance of pancreatic cancer.
Li L; Leung PS
Int J Biochem Cell Biol; 2014 Aug; 53():224-36. PubMed ID: 24875648
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
[TBL] [Abstract][Full Text] [Related]
19. Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells.
Zhu X; Shen X; Qu J; Straubinger RM; Jusko WJ
CPT Pharmacometrics Syst Pharmacol; 2018 Sep; 7(9):549-561. PubMed ID: 30084546
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
